Rhumbline Advisers Adaptimmune Therapeutics PLC Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
A detailed history of Rhumbline Advisers transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Rhumbline Advisers holds 7,122 shares of ADAP stock, worth $7,264. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,122
Previous 5,912
20.47%
Holding current value
$7,264
Previous $4,000
175.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ADAP
# of Institutions
84Shares Held
160MCall Options Held
42.8KPut Options Held
42.1K-
Matrix Capital Management Company, LP Waltham, MA39MShares$39.8 Million0.57% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$28 Million1.23% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$17.4 Million1.89% of portfolio
-
Baillie Gifford & CO15.9MShares$16.2 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY10.8MShares$11 Million0.22% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $167M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...